Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Hell J Nucl Med ; 25(2): 188-195, 2022.
Article in English | MEDLINE | ID: mdl-36030461

ABSTRACT

OBJECTIVE: Epidermal growth factor receptor mutations (EGFRm) and rearrangement of the anaplastic lymphoma kinase gene (ALKr) can be targeted for precision therapy in lung adenocarcinoma (LADC). As molecular profiling is not available for all, patient stratification can be achieved using non-invasive and economic tools, such as positron emission tomography/computed tomography (PET/CT). We aimed to evaluate the relationships between fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT maximum standardized uptake value (SUVmax) of primary tumors (pSUVmax) and lymph nodes (nSUVmax) and the EGFRm and ALKr status in a large series of Turkish LADC patients. MATERIAL AND METHODS: In this retrospective study, medical records of histopathologically confirmed LADC patients were reviewed for demographic and clinical data. The 18F-FDG PET/CT pSUVmax nSUVmax were calculated and analyzed for their relationships with EGFRm and ALKr using multiple regression analysis. RESULTS: The study population consisted of 732 LADC patients with a mean age of 63±10 years. The frequencies of EGFRm and ALKr were 10.4% and 3.6%, respectively. Female gender, being a former- or never-smoker for EGFRm and age for ALKr were determined as independent risk factors (P<0.05). No significant differences in pSUVmax and nSUVmax were present between the patients with either EGFRm or ALKr compared to the wild-type genotype patients (P>0.05). CONCLUSION: We conclude that 18F-FDG PET/CT semi-quantitative parameter SUVmax could not be validated for the prediction of the EGFRm or the ALKr in our large series of 732 Turkish patients with LADC.


Subject(s)
Adenocarcinoma of Lung , Anaplastic Lymphoma Kinase , ErbB Receptors , Lung Neoplasms , Aged , Anaplastic Lymphoma Kinase/genetics , ErbB Receptors/genetics , Female , Fluorodeoxyglucose F18 , Humans , Male , Middle Aged , Mutation , Positron Emission Tomography Computed Tomography , Retrospective Studies , Turkey
2.
Front Med (Lausanne) ; 8: 788551, 2021.
Article in English | MEDLINE | ID: mdl-35186972

ABSTRACT

INTRODUCTION: The search for biomarkers that could help in predicting disease prognosis in the Coronavirus Disease-2019 (COVID-19) outbreak is still high on the agenda. OBJECTIVE: To find out the efficacy of D-dimer and mean platelet volume (MPV) combination as a prognostic marker in hospitalized COVID-19 patients with bilateral infiltration. MATERIALS AND METHODS: Study design: Retrospective observational cohort. Patients who were presented to our hospital between March 16, 2020 and June 07, 2020 were reviewed retrospectively. The primary outcome of the study was specified as the need for intensive care, while the secondary outcomes were duration of treatment and hospitalization. Receiver operator curve (ROC) analyzes were carried out to assess the efficacy of D-dimer and MPV parameters as prognostic markers. RESULTS: Between the mentioned dates, 575 of 1,564 patients were found to be compatible with COVID-19, and the number of patients who were included in the study was 306. The number of patients who developed the need for intensive care was 40 (13.1%). For serum D-dimer levels in assessing the need for intensive care, the area under the curve (AUC) was found to be 0.707 (95% CI: 0.620-0.794). The AUC for MPV was 0.694 (95% CI: 0.585-0.803), when D-dimer was ≥1.0 mg/L. When patients with a D-dimer level of ≥1.0 mg/L were divided into two groups considering the MPV cut-off value as 8.1, the rate of intensive care transport was found to be significantly higher in patients with an MPV of ≥8.1 fL compared to those with an MPV of <8.1 fL (32.6 vs. 16.0%, p = 0.043). For the prognostic efficacy of the combination of D-dimer ≥ 1.0 mg/L and MPV ≥ 8.1 fL in determining the need for intensive care, following values were determined: sensitivity: 57.7%, specificity: 70.8%, positive predictive value (PPV): 32.0%, negative predictive value (NPV): 84.0%, and accuracy: 63.0%. When D-dimer was ≥1.0, the median duration of treatment in MPV <8.1 and ≥8.1 groups was 5.0 [interquartile range (IQR): 5.0-10.0] days for both groups (p = 0.64). The median length of hospital stay (LOS) was 7.0 (IQR: 5.0-10.5) days in the MPV <8.1 group, while it was 8.5 (IQR: 5.0-16.3) days in the MPV ≥ 8.1 group (p = 0.17). CONCLUSION: In COVID-19 patients with a serum D-dimer level of at least 1.0 mg/L and radiological bilateral infiltration at hospitalization, if the MPV value is ≥8.1, we could predict the need for intensive care with moderate efficacy and a relatively high negative predictive value. However, no correlation could be found between this combined marker and the duration of treatment and the LOS.

3.
Tuberk Toraks ; 68(2): 96-102, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32755108

ABSTRACT

INTRODUCTION: The aim of the present study is to investigate the diagnostic value of the CD4+, CD8+ and CD103+ lymphocyte sub-groups in mediastinal lymph nodes, as an adjunctive marker in sarcoidosis. MATERIALS AND METHODS: The present study is a single-center, prospective cohort study designed in a reference center for chest diseases. Forty-six patients who underwent endobronchial ultrasound (EBUS)-guided mediastinal lymph node sampling with a preliminary diagnosis of sarcoidosis were enrolled. The different lymphocyte subgroups were counted by flow cytomeytry in lymph node biopsy samples. Based on the final diagnosis, subjects were divided into two groups: sarcoidosis and non-sarcoidosis. Lymphocyte subset analysis were compared between the groups. RESULT: The final diagnoses were sarcoidosis in 31 (67%) and non-sarcoidosis in 15 patients (33%). The total cell counts, lymphocyte ratios, CD8+ T lymphocyte ratios and CD4/CD8 ratios were similar in both groups (p> 0.05). CD4+ T lymphocyte rates were higher in patients with sarcoidosis (p= 0.017). CD103 subset analysis revealed significantly lower CD103+CD4+, CD103+CD8+ lymphocytes and CD103+CD4+/CD4+ ratios in sarcoidosis (p= 0.008, p= 0.048, p= 0.014, respectively). CONCLUSIONS: Cytological examination of EBUS-guided lymph node samples may provide substantial findings in differential diagnosis of sarcoidosis. Patients with sarcoidosis have higher CD4+ lymphocytes, lower CD103+CD4+ lymphocytes and CD103+CD4+/CD4+ and CD103+CD8+ lymphocyte ratios. These subsets of lymphocytes in lymph node biopsies may be novel predictors of sarcoidosis diagnosis.


Subject(s)
CD4-CD8 Ratio , CD4-Positive T-Lymphocytes/pathology , CD8-Positive T-Lymphocytes/pathology , Sarcoidosis/diagnostic imaging , Sarcoidosis/pathology , Adult , Biomarkers/analysis , Biopsy , Female , Humans , Lymph Nodes/pathology , Male , Mediastinum/pathology , Middle Aged , Prospective Studies , Ultrasonography
4.
Int J Chron Obstruct Pulmon Dis ; 13: 1261-1267, 2018.
Article in English | MEDLINE | ID: mdl-29713159

ABSTRACT

PURPOSE: The aim of this study was to evaluate the impact of exposure to biomass smoke vs cigarette smoke on serum inflammatory markers and pulmonary function parameters in patients with chronic respiratory failure (CRF). PATIENTS AND METHODS: A total of 106 patients with CRF divided into age and gender-matched groups of cigarette-smoke exposure (n=55, mean [SD] age: 71.0 [12.0] years, 92.7% were females) and biomass smoke exposure (n=51, mean [SD] age: 73.0 [11.0] years, 94.1% were females) were included in this retrospective study. Data on patient demographics (age and gender), inflammatory markers, including neutrophil-to-lymphocyte ratio, C-reactive protein, platelet/mean platelet volume ratio, arterial blood gas analysis, and pulmonary function test findings, including forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC were obtained from medical records. RESULTS: Carbon dioxide partial pressure levels were significantly higher in the biomass smoke exposure than in the cigarette smoke exposure group (mean [SD] 51.0 [8.0] vs 47.0 [8.0] mmHg, p=0.026, respectively). Spirometry revealed similarly low levels for FEV1 (%) (38.0 [16.0] vs 40.0 [12.0]%) and FVC (%) (45.0 [19.0] vs 39.0 [19.0]%) in cigarette-smoke and biomass smoke exposure groups, whereas biomass smoke exposure was associated with significantly higher FEV1/FVC (75.0 [14.0] vs 58.0 [12.0]%, p=0.001), lower FVC (mL) (mean [SD] 744.0 [410.0] vs 1,063.0 [592.0] mL, p=0.035) and lower percentage of patients with FEV1/FVC <70% (36.8% vs 82.0%, p<0.001) than cigarette smoke exposure. CONCLUSION: Our findings indicate similarly increased inflammatory markers and abnormally low pulmonary function test findings in both biomass smoke exposure and cigarette smoke exposure groups, emphasizing the adverse effects of biomass smoke exposure on lungs to be as significant as cigarette smoke exposure. Association of biomass smoke exposure with higher likelihood of FEV1/FVC ratio of >70% and more prominent loss of vital capacity than cigarette smoke exposure seems to indicate the likelihood of at least 18 years of biomass exposure to be sufficiently high to be responsible for both obstructive and restrictive pulmonary diseases.


Subject(s)
Biomass , Cigarette Smoking/adverse effects , Inflammation Mediators/blood , Lung/physiopathology , Respiratory Insufficiency/etiology , Smoke/adverse effects , Aged , Aged, 80 and over , Biomarkers/blood , Chronic Disease , Female , Forced Expiratory Volume , Humans , Lung/metabolism , Lymphocyte Count , Male , Medical Records , Middle Aged , Platelet Count , Prognosis , Respiratory Insufficiency/blood , Respiratory Insufficiency/diagnosis , Respiratory Insufficiency/physiopathology , Retrospective Studies , Risk Assessment , Risk Factors , Spirometry , Time Factors , Vital Capacity
5.
Eurasian J Med ; 49(3): 161-166, 2017 Oct.
Article in English | MEDLINE | ID: mdl-29123437

ABSTRACT

OBJECTIVE: While the incidence of sarcoidosis peaks between 20 and 39 years, it is comparatively low in elderly subjects. We sought to determine whether there are age-dependent differences in the demographic and laboratory characteristics of patients with sarcoidosis. MATERIALS AND METHODS: We retrospectively collected information from our database using the International Classification of Disease (ICD) diagnostic code D86 between 2008 and 2014. Patients were divided into three groups: 20-39 years old (Group 1), 40-59 years old (Group 2), and 60-80 years old (Group 3). RESULTS: A total of 3988 patients with code of D86 were included in the study. After the exclusion of non-eligible patients, the number of cases in Groups 1, 2, and 3 were 276, 641, and 352, respectively. The groups were compared according to demographic characteristics, ICD diagnostic codes, and laboratory parameters. The ratio of female patients was significantly higher in Group 3 than in Groups 1 and 2 (p=0.000). There was no difference in diagnostic codes of the ICD subgroups between groups (p=0.19). While the level of blood-urea nitrogen was significantly higher in Group 3 patients than in other groups (p=0.000), serum angiotensin-converting enzyme (ACE) values were found to be significantly low in Group 3 (p=0.010). The mean ACE values did not differ between females and males (50.8±39.3 and 59.1±45.5 mg/dL, respectively) (p=0.18). CONCLUSION: The majority of patients with sarcoidosis were female in all age groups and pulmonary sarcoidosis was the most common presentation of the disease. Elderly patients (≥60 years) with sarcoidosis had lower serum ACE levels than younger patients.

6.
Clin EEG Neurosci ; 48(1): 54-59, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27107024

ABSTRACT

Sarcoidosis is a multisystem granulomatous disease affecting nervous system in 5% to 10% of patients. Magnetic resonance imaging (MRI) is accepted as the most sensitive method for detecting neurosarcoidosis. However, the most common findings in MRI are the nonspecific white matter lesions, which may be unrelated to sarcoidosis and can occur because of hypertension, diabetes mellitus, smoking, and other inflammatory or infectious disorders, as well. Autopsy studies report more frequent neurological involvement than the ante mortem studies. The aim of this study is to assess electroencephalography (EEG) in sarcoidosis patients without neurological findings in order to display asymptomatic neurological dysfunction. We performed EEG on 30 sarcoidosis patients without diagnosis of neurosarcoidosis or prior neurological comorbidities. Fourteen patients (46.7%) showed intermittant focal and/or generalized slowings while awake and not mentally activated. Seven (50%) of these 14 patients with EEG slowings had nonspecific white matter changes while the other half showed EEG slowings in the absence of MRI changes. We conclude that EEG slowings, when normal variants (psychomotor variant, temporal theta of elderly, frontal theta waves) are eliminated, may be an indicator of dysfunction in brain activity even in the absence of MRI findings. Hence, EEG may contribute toward detecting asymptomatic neurological dysfunction or probable future neurological involvement in sarcoidosis patients.


Subject(s)
Asymptomatic Diseases , Brain/physiopathology , Central Nervous System Diseases/diagnosis , Central Nervous System Diseases/physiopathology , Diagnosis, Computer-Assisted/methods , Electroencephalography/methods , Sarcoidosis/diagnosis , Sarcoidosis/physiopathology , Adult , Female , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
7.
Clin Respir J ; 11(6): 935-941, 2017 Nov.
Article in English | MEDLINE | ID: mdl-26720178

ABSTRACT

OBJECTIVES: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a new, minimally invasive, bronchoscopic technique used in the evaluation of inthrathoracic lymph nodes.Use of sedation drugs before the procedure differs among centres. There is no standardization about sedation before EBUS-TBNA.We used a policy decision to shift from use of propofol with midazolam vs midazolam alone in a large tertiary hospital to evaluate the diagnostic yield and safety of EBUS-TBNA procedure. METHODS: Files of all the patients who were performed EBUS-TBNA between the dates of September 2010 and May 2014 were surveyed. All the EBUS-TBNA cases were performed under sedation of propofol and midazolam with an accompanying anesthesiologist in the beginning, however, sedation is applied with midazolam without an accompanying anesthesiologist after April 2013 due to changes in sedation policy. The diagnostic yield and complication rates were compared by chi-squared analysis between two groups. RESULTS: The files of 340 EBUS-TBNA performed patients were evaluated. Of the patients 274 eligible patients were analysed. 152 patients who fulfilled the inclusion criteria were analysed in propofol-midazolam (P) sedated group and 122 patients were analysed in midazolam (M) group. There is no statistically significant difference between two different sedated groups in terms of age and gender. Diagnostic value was detected as 77.6% in P group and 85.7% in M group and the difference was not statistically significant. No difference between complication rates of both groups was observed. CONCLUSION: Both sedation-types for performing EBUS-TBNA showed similar diagnostic value and complication rates in our study. Propofol with midazolam application requires with an accompanying anaesthesiologist, therefore, it increases cost. EBUS-TBNA procedures had been performed in safe with no decrease in diagnostic yield under moderate sedation.


Subject(s)
Bronchoscopy/methods , Conscious Sedation/adverse effects , Endoscopic Ultrasound-Guided Fine Needle Aspiration/methods , Image-Guided Biopsy/methods , Midazolam/pharmacology , Propofol/pharmacology , Adjuvants, Anesthesia/pharmacology , Aged , Anesthetics, Combined/pharmacology , Bronchoscopy/adverse effects , Conscious Sedation/trends , Endoscopic Ultrasound-Guided Fine Needle Aspiration/adverse effects , Female , Humans , Hypnotics and Sedatives/pharmacology , Lymph Nodes/pathology , Male , Mediastinum/pathology , Midazolam/administration & dosage , Middle Aged , Propofol/administration & dosage , Retrospective Studies
8.
Tuberk Toraks ; 64(2): 119-26, 2016 Jun.
Article in Turkish | MEDLINE | ID: mdl-27481078

ABSTRACT

INTRODUCTION: Malnutrition is a comorbidity oftenly seen in COPD patients who have progressive chronic inflammation and severity. In this prospective study, we aimed to determine the nutritional status of stable COPD patients and to investigate the impact of nutritional status on perception of dyspnoea, exercise capacity, body composition, hospitalisation and life quality. MATERIALS AND METHODS: COPD patients were assessed using previous smoking story, physical examination and irreversible airway obstruction. This study was done with 50 COPD patients older than 65 years of age and 30 control subjects. Exclusion criteria were also the co-existance of malignancies, malabsorbtion, DM, neurological diseases, renal failure and unstable cardiac diseases known to influence the nutritional state. The obstruction degree was evaluated by spirometry, nutritional status was classified by the MNA questionnaire, perception of dyspnoea was assessed by the MMRC scale, exercise capacity was assessed by the 6MWT, life quality was assessed by the CAT scale. Body composition parameters FM, FFM and FMI were analyzed and hospitalisations during 6 months after discharge were recorded. RESULT: The COPD patients were divided into three groups as without malnutrition (n= 25,%50), under risk of malnutrition (n= 19,%38) and malnourished (n= 6,%12). The COPD severity, MMRC dyspnoea score, CAT score and hospitalisations during 6 months following were higher among the malnourished patients. On the other hand, body mass index, 6MWT results, FM and FFM were lower in malnourished patients. A positive correlation between FFM and 6MWT and a negative correlation between FFM and hospitalisation were observed. CONCLUSIONS: MNA is a well-developed questionnaire which evaluates malnutrition in COPD patients. We determined that malnourished COPD patients have higher airway obstruction degree, perception of dyspnoea, CAT score and lower exercise capacity and FFM. FFM is an independent predictor of exercise capacity and rehospitalisation during 6 months.


Subject(s)
Body Composition/physiology , Dyspnea/etiology , Exercise Tolerance/physiology , Hospitalization , Nutritional Status/physiology , Pulmonary Disease, Chronic Obstructive/physiopathology , Quality of Life , Aged , Body Mass Index , Case-Control Studies , Comorbidity , Exercise Test , Female , Humans , Male , Middle Aged , Prospective Studies , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Disease, Chronic Obstructive/diagnosis , Surveys and Questionnaires
9.
Article in English | MEDLINE | ID: mdl-27330283

ABSTRACT

PURPOSE: Noninvasive mechanical ventilation (NIMV) usage outside of intensive care unit is not recommended in patients with COPD for severe acute respiratory failure (ARF). We assessed the factors associated with failure of NIMV in patients with ARF and severe acidosis admitted to the emergency department and followed on respiratory ward. PATIENTS AND METHODS: This is a retrospective observational cohort study conducted in a tertiary teaching hospital specialized in chest diseases and thoracic surgery between June 1, 2013 and May 31, 2014. COPD patients who were admitted to our emergency department due to ARF were included. Patients were grouped according to the severity of acidosis into two groups: group 1 (pH=7.20-7.25) and group 2 (pH=7.26-7.30). RESULTS: Group 1 included 59 patients (mean age: 70±10 years, 30.5% female) and group 2 included 171 patients (mean age: 67±11 years, 28.7% female). On multivariable analysis, partial arterial oxygen pressure to the inspired fractionated oxygen (PaO2/FiO2) ratio <200, delta pH value <0.30, and pH value <7.31 on control arterial blood gas after NIMV in the emergency room and peak C-reactive protein were found to be the risk factors for NIMV failure in COPD patients with ARF in the ward. CONCLUSION: NIMV is effective not only in mild respiratory failure but also with severe forms of COPD patients presenting with severe exacerbation. The determination of the failure criteria of NIMV and the expertise of the team is critical for treatment success.


Subject(s)
Lung/physiopathology , Noninvasive Ventilation/methods , Pulmonary Disease, Chronic Obstructive/therapy , Respiratory Insufficiency/therapy , Acidosis/physiopathology , Acidosis/therapy , Aged , Aged, 80 and over , Biomarkers/blood , C-Reactive Protein/metabolism , Chi-Square Distribution , Disease Progression , Female , Hospitals, Teaching , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Noninvasive Ventilation/adverse effects , Noninvasive Ventilation/mortality , Oxygen/blood , Partial Pressure , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/mortality , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory Insufficiency/blood , Respiratory Insufficiency/mortality , Respiratory Insufficiency/physiopathology , Retrospective Studies , Risk Factors , Severity of Illness Index , Tertiary Care Centers , Treatment Failure
10.
Article in English | MEDLINE | ID: mdl-26648709

ABSTRACT

BACKGROUND: COPD exacerbations requiring hospitalization increase morbidity and mortality. Although most COPD exacerbations are neutrophilic, approximately 10%-25% of exacerbations are eosinophilic. AIM: We aimed to evaluate mortality and outcomes of eosinophilic and non-eosinophilic COPD exacerbations and identify new biomarkers that predict survival. METHODS: A retrospective observational cohort study was carried out in a tertiary teaching hospital from January 1, 2014 to November 1, 2014. All COPD patients hospitalized with exacerbations were enrolled in the study at their initial hospitalization and followed-up for 6 months after discharge. Electronic data were collected from the hospital database. Subjects' characteristics, hemogram parameters, CRP levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-mean platelet volume ratio on admission and discharge, length of hospital stay (days), readmissions, and mortality were recorded. Patients were grouped according to peripheral blood eosinophil (PBE) levels: Group 1, >2% PBE, eosinophilic; Group 2, non-eosinophilic ≤2%. Patient survival after hospital discharge was evaluated by Kaplan-Meier survival analysis. RESULTS: A total of 1,704 patients hospitalized with COPD exacerbation were included. Approximately 20% were classified as eosinophilic. Six-month mortality was similar in eosinophilic and non-eosinophilic groups (14.2% and 15.2%, respectively); however, the hospital stay length and readmission rate were longer and higher in the non-eosinophilic group (P<0.001 and P<0.01, respectively). CRP and NLR were significantly higher in the non-eosinophilic group (both P<0.01). The platelet-to-mean platelet volume ratio was not different between the two groups. Cox regression analysis showed that survival was negatively influenced by elevated CRP (P<0.035) and NLR (P<0.001) in the non-eosinophilic group. CONCLUSION: Non-eosinophilic patients with COPD exacerbations with high CRP and NLR values had worse outcomes than eosinophilic patients. PBE and NLR can be helpful markers to guide treatment decisions.


Subject(s)
Inflammation Mediators/immunology , Patient Readmission , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/immunology , Pulmonary Eosinophilia/diagnosis , Pulmonary Eosinophilia/immunology , Aged , Aged, 80 and over , Biomarkers/blood , Blood Platelets/immunology , C-Reactive Protein/immunology , Chi-Square Distribution , Disease Progression , Female , Hospitals, Teaching , Humans , Inflammation Mediators/blood , Kaplan-Meier Estimate , Lymphocyte Count , Lymphocytes/immunology , Male , Mean Platelet Volume , Middle Aged , Neutrophils/immunology , Platelet Count , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/mortality , Pulmonary Disease, Chronic Obstructive/therapy , Pulmonary Eosinophilia/blood , Pulmonary Eosinophilia/mortality , Pulmonary Eosinophilia/therapy , Retrospective Studies , Risk Assessment , Risk Factors , Tertiary Care Centers , Time Factors , Turkey
11.
Article in English | MEDLINE | ID: mdl-26648713

ABSTRACT

INTRODUCTION: The objective of this study was to compare the change in 6-minute walking distance (6MWD) in 1 year as an indicator of exercise capacity among patients undergoing home non-invasive mechanical ventilation (NIMV) due to chronic hypercapnic respiratory failure (CHRF) caused by different etiologies. METHODS: This retrospective cohort study was conducted in a tertiary pulmonary disease hospital in patients who had completed 1-year follow-up under home NIMV because of CHRF with different etiologies (ie, chronic obstructive pulmonary disease [COPD], obesity hypoventilation syndrome [OHS], kyphoscoliosis [KS], and diffuse parenchymal lung disease [DPLD]), between January 2011 and January 2012. The results of arterial blood gas (ABG) analyses and spirometry, and 6MWD measurements with 12-month interval were recorded from the patient files, in addition to demographics, comorbidities, and body mass indices. The groups were compared in terms of 6MWD via analysis of variance (ANOVA) and multiple linear regression (MLR) analysis (independent variables: analysis age, sex, baseline 6MWD, baseline forced expiratory volume in 1 second, and baseline partial carbon dioxide pressure, in reference to COPD group). RESULTS: A total of 105 patients with a mean age (± standard deviation) of 61±12 years of whom 37 had COPD, 34 had OHS, 20 had KS, and 14 had DPLD were included in statistical analysis. There were no significant differences between groups in the baseline and delta values of ABG and spirometry findings. Both univariate ANOVA and MLR showed that the OHS group had the lowest baseline 6MWD and the highest decrease in 1 year (linear regression coefficient -24.48; 95% CI -48.74 to -0.21, P=0.048); while the KS group had the best baseline values and the biggest improvement under home NIMV (linear regression coefficient 26.94; 95% CI -3.79 to 57.66, P=0.085). CONCLUSION: The 6MWD measurements revealed improvement in exercise capacity test in CHRF patients receiving home NIMV treatment on long-term depends on etiological diagnoses.


Subject(s)
Exercise Tolerance , Home Care Services , Lung/physiopathology , Noninvasive Ventilation/methods , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory Insufficiency/physiopathology , Adult , Aged , Blood Gas Analysis , Chi-Square Distribution , Chronic Disease , Exercise Test , Female , Forced Expiratory Volume , Humans , Linear Models , Male , Middle Aged , Multivariate Analysis , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/therapy , Recovery of Function , Respiratory Insufficiency/diagnosis , Respiratory Insufficiency/etiology , Respiratory Insufficiency/therapy , Retrospective Studies , Risk Factors , Spirometry , Tertiary Care Centers , Time Factors , Treatment Outcome , Walking
12.
Article in English | MEDLINE | ID: mdl-26392758

ABSTRACT

BACKGROUND: COPD exacerbations requiring intensive care unit (ICU) admission have a major impact on morbidity and mortality. Only 10%-25% of COPD exacerbations are eosinophilic. AIM: To assess whether eosinophilic COPD exacerbations have better outcomes than non-eosinophilic COPD exacerbations in the ICU. METHODS: This retrospective observational cohort study was conducted in a thoracic, surgery-level III respiratory ICU of a tertiary teaching hospital for chest diseases from 2013 to 2014. Subjects previously diagnosed with COPD and who were admitted to the ICU with acute respiratory failure were included. Data were collected electronically from the hospital database. Subjects' characteristics, complete blood count parameters, neutrophil to lymphocyte ratio (NLR), delta NLR (admission minus discharge), C-reactive protein (CRP) on admission to and discharge from ICU, length of ICU stay, and mortality were recorded. COPD subjects were grouped according to eosinophil levels (>2% or ≤2%) (group 1, eosinophilic; group 2, non-eosinophilic). These groups were compared with the recorded data. RESULTS: Over the study period, 647 eligible COPD subjects were enrolled (62 [40.3% female] in group 1 and 585 [33.5% female] in group 2). Group 2 had significantly higher C-reactive protein, neutrophils, NLR, delta NLR, and hemoglobin, but a lower lymphocyte, monocyte, and platelet count than group 1, on admission to and discharge from the ICU. Median (interquartile range) length of ICU stay and mortality in the ICU in groups 1 and 2 were 4 days (2-7 days) vs 6 days (3-9 days) (P<0.002), and 12.9% vs 24.9% (P<0.034), respectively. CONCLUSION: COPD exacerbations with acute respiratory failure requiring ICU admission had a better outcome with a peripheral eosinophil level >2%. NLR and peripheral eosinophilia may be helpful indicators for steroid and antibiotic management.


Subject(s)
Disease Progression , Eosinophilia/blood , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/complications , Respiratory Insufficiency/mortality , Aged , C-Reactive Protein/analysis , Female , Hospitals, Teaching , Humans , Intensive Care Units , Length of Stay , Logistic Models , Male , Middle Aged , Retrospective Studies , Risk Factors , Tertiary Care Centers
13.
J Cardiothorac Surg ; 2: 52, 2007 Dec 03.
Article in English | MEDLINE | ID: mdl-18053192

ABSTRACT

Bronchobiliary fistula (BBF), which often presents with bilioptysis, is an abnormal communication between the bronchial system and biliary tree. It is a complication associated with a high mortality rate and requires a well-planned management strategy. Although hydatid disease is still the leading cause, extensive surgical interventions and invasive procedures of the liver have altered the profile of patients in recent decades. This paper presents 3 cases of BBF and reviews the literature regarding the treatment options generally mandated by clinical presentation and the underlying disease.


Subject(s)
Biliary Fistula/diagnosis , Biliary Fistula/surgery , Bronchial Fistula/diagnosis , Bronchial Fistula/surgery , Adult , Biliary Fistula/etiology , Bilirubin/blood , Bronchial Fistula/etiology , Cholangiography/methods , Diaphragm/surgery , Humans , Magnetic Resonance Imaging , Male , Thoracotomy , Tomography, X-Ray Computed , Wounds, Gunshot/complications , Young Adult
14.
Acta Orthop Traumatol Turc ; 40(3): 255-9, 2006.
Article in Turkish | MEDLINE | ID: mdl-16905901

ABSTRACT

Three patients with synovial tuberculosis are presented. Involvement was in the hand in one patient, and in the wrist in two patients. None of the patients had pulmonary tuberculosis or a family history of tuberculosis. Tuberculosis treatment was initiated only after histologic verification. The cultures remained negative. The patients received a 12-month course of multidrug chemotherapy for tuberculosis, resulting in symptomatic improvement and healing. There were no recurrences during a follow-up period of 16 to 26 months. Our clinical observations showed that tuberculosis tenosynovitis benefited well from antituberculosis chemotherapy.


Subject(s)
Hand Joints/pathology , Tenosynovitis/diagnosis , Tuberculosis, Osteoarticular/diagnosis , Wrist Joint/pathology , Adolescent , Adult , Antitubercular Agents/therapeutic use , Diagnosis, Differential , Drug Administration Schedule , Female , Humans , Middle Aged , Radiography , Tenosynovitis/diagnostic imaging , Tenosynovitis/drug therapy , Tenosynovitis/pathology , Tuberculosis, Osteoarticular/diagnostic imaging , Tuberculosis, Osteoarticular/drug therapy , Tuberculosis, Osteoarticular/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...